"10.1371_journal.pone.0065776","plos one","2013-06-14T00:00:00Z","Michaël Schwarzinger; Luis Sagaon-Teyssier; Odile Cabaret; Stéphane Bretagne; Catherine Cordonnier; for the PREVERT Investigators","Equipe ATIP/AVENIR, INSERM, UMR 738, Paris, France; Univ Paris Diderot, Sorbonne Paris Cité, UMR 738, Paris, France; Translational Health Economics Network, Paris, France; Center for Health Policy, Stanford University, Stanford, California, United States of America; INSERM, UMR912 (SESSTIM), Marseille, France; Univ Aix Marseille, UMR_S912, IRD, Marseille, France; ORS PACA, Observatoire Régional de la Santé Provence-Alpes-Côte dAzur, Marseille, France; Parasitology-Mycology Department, Henri Mondor Teaching Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France; Univ Paris-Est-Créteil, UMR 956, Créteil, France; Institut Pasteur, Centre National de Référence des Mycoses Invasives et Antifongiques, Paris, France; Hematology Department, Henri Mondor Teaching Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Créteil, France","¶ The PREVERT Investigators are listed in the Acknowledgments.","This work was supported in part by the French Ministry of Health (research grant PHRC 2002 AOR02028) and Translational Health Economics Network, a for-profit organization led by Michaël Schwarzinger. Stéphane Bretagne is consultant for Gilead Sciences, and has received speaking honoraria from Pfizer and Gilead Sciences and travel grants from Astellas, Pfizer and Schering-Plough. Catherine Cordonnier has received travel grants and research supports from Pfizer, Gilead, and Merck Sharp & Dohme-Chibret, and has been a consultant for Pfizer, Schering-Plough, Gilead, Merck Sharp & Dohme-Chibret, Astellas Pharma, and Zeneus Pharma. All other authors: no conflict of interest. There are no patents, products in development or marketed products to declare. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2013","06","Michaël Schwarzinger","MS",6,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
